Hepcvel (Sofosbuvir 400mg + Velpatasvir 100mg)

Hepcvel (Sofosbuvir 400mg + Velpatasvir 100mg) 28 tab

Manufacturer: Cipla Ltd. (India)

Product Description

Hepcvel is a fixed-dose antiviral combination developed by Cipla Ltd. for the treatment of chronic Hepatitis C virus (HCV) infection in adults.
Each tablet contains Sofosbuvir (400 mg) and Velpatasvir (100 mg), providing a pan-genotypic solution effective against all six major genotypes of HCV.

Mechanism of Action

• Sofosbuvir inhibits the NS5B RNA-dependent polymerase, preventing viral replication.
• Velpatasvir inhibits the NS5A protein, blocking viral assembly and release.

Together, they effectively suppress HCV replication and help achieve sustained virologic response (SVR) in over 95% of patients.

Indications

• Chronic Hepatitis C infection (Genotypes 1–6)
• Suitable for patients with compensated liver cirrhosis
• Used as part of interferon-free therapy

Dosage & Administration

• Recommended dose: One tablet daily (Sofosbuvir 400mg + Velpatasvir 100mg)
• Can be taken with or without food
• Usual treatment duration: 12 weeks, as prescribed by a physician

Side Effects

Hepcvel is generally well tolerated. Possible mild side effects include:

• Headache
• Fatigue
• Nausea
• Insomnia

Most side effects are temporary and do not require discontinuation of therapy.

Advantages

• Effective for all HCV genotypes
• High cure rate (SVR > 95%)
• Once-daily oral tablet
• Reliable quality from Cipla Ltd., a trusted global pharmaceutical company

Storage

• Store below 30°C
• Keep in a cool, dry place away from direct sunlight
• Keep out of reach of children